Davita (DVA) Downgraded to C+ at TheStreet

Share on StockTwits

TheStreet lowered shares of Davita (NYSE:DVA) from a b- rating to a c+ rating in a research note released on Thursday morning.

Other equities analysts also recently issued research reports about the stock. ValuEngine raised shares of Davita from a hold rating to a buy rating in a research note on Tuesday, October 9th. Zacks Investment Research raised shares of Davita from a hold rating to a buy rating and set a $81.00 price target for the company in a research note on Monday, October 8th. Raymond James downgraded shares of Davita from a strong-buy rating to a market perform rating in a research note on Thursday. JPMorgan Chase & Co. raised shares of Davita from an underweight rating to a neutral rating in a research note on Thursday, September 13th. Finally, Royal Bank of Canada raised their price target on shares of Davita from $70.00 to $78.00 and gave the company a sector perform rating in a research note on Thursday. Seven investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of Hold and a consensus price target of $84.75.

Shares of DVA stock traded down $0.45 during trading hours on Thursday, hitting $69.70. 2,486,230 shares of the company’s stock traded hands, compared to its average volume of 1,943,652. The company has a market capitalization of $12.70 billion, a P/E ratio of 20.99, a PEG ratio of 0.98 and a beta of 1.09. Davita has a 12 month low of $53.78 and a 12 month high of $80.71. The company has a debt-to-equity ratio of 1.82, a quick ratio of 1.88 and a current ratio of 1.90.

Davita (NYSE:DVA) last released its quarterly earnings results on Wednesday, November 7th. The company reported $0.56 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.89 by ($0.33). The business had revenue of $2.85 billion for the quarter, compared to the consensus estimate of $2.93 billion. Davita had a net margin of 5.39% and a return on equity of 13.37%. Davita’s revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.81 EPS. As a group, sell-side analysts forecast that Davita will post 4 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Atlas Capital Advisors LLC increased its position in shares of Davita by 247.9% during the third quarter. Atlas Capital Advisors LLC now owns 2,592 shares of the company’s stock worth $188,000 after buying an additional 1,847 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in shares of Davita during the second quarter worth $206,000. Green Square Capital LLC acquired a new stake in shares of Davita during the second quarter worth $208,000. IFG Advisory LLC acquired a new stake in shares of Davita during the second quarter worth $213,000. Finally, Seven Eight Capital LP acquired a new stake in shares of Davita during the third quarter worth $219,000. Institutional investors own 87.36% of the company’s stock.

Davita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Story: Put Option

Analyst Recommendations for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Micro Focus International  Upgraded to Buy by Goldman Sachs Group
Micro Focus International Upgraded to Buy by Goldman Sachs Group
Tesco  Downgraded by Zacks Investment Research
Tesco Downgraded by Zacks Investment Research
Qorvo  Price Target Cut to $75.00
Qorvo Price Target Cut to $75.00
Barrington Research Analysts Give Stericycle  a $64.00 Price Target
Barrington Research Analysts Give Stericycle a $64.00 Price Target
Arsanis  Downgraded by Zacks Investment Research
Arsanis Downgraded by Zacks Investment Research
BMC Stock  Downgraded by BidaskClub to “Strong Sell”
BMC Stock Downgraded by BidaskClub to “Strong Sell”


Leave a Reply

© 2006-2018 Ticker Report